<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841149</url>
  </required_header>
  <id_info>
    <org_study_id>NI18037J</org_study_id>
    <secondary_id>2018-A01394-51</secondary_id>
    <nct_id>NCT03841149</nct_id>
  </id_info>
  <brief_title>Volume 3D_US Kidney</brief_title>
  <acronym>VolUS3D</acronym>
  <official_title>Measurement of Kidney Volume and Renal Tumor Volume Using 3D-Ultrasound Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the volume of the kidney and tumors using 3D-US
      acquisition and to correlate these measurements to contrast-enhanced CT or MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional objectives are comparison between true volume measurements and volume estimation
      using measurements of the three perpendicular diameters, comparison of inter and intra
      variability of 3D US measurements with inter and intra variability of 3D CT or MRI
      measurements, calculation of 3D and 2D volume measurements during contrast-enhanced US
      examination when the injection is performed for clinical routine purposes such as vascular
      and extension staging, during interventional procedures such as US guided biopsy targeting
      the non-necrotic tumour parenchyma. Concordance between 2D and 3D US acquisitions will be
      compared to CT and MRI measurements. Comparison of volume measurements between non-contrast
      and contrast-enhanced methods (US, CT and MRI) will be performed. The results will be
      compared to renal function before and after tumour treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3D-US volume measurements</measure>
    <time_frame>1 month</time_frame>
    <description>Kidney and renal tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2D-US volume measurements</measure>
    <time_frame>1 month</time_frame>
    <description>Kidney and renal tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter and intra variability measurements</measure>
    <time_frame>1 month</time_frame>
    <description>Kidney and renal tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2D and 3D US volume measurements during Contrast-enhanced US (if performed for patient management)</measure>
    <time_frame>1 month</time_frame>
    <description>Kidney and renal tumor</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>VolUS3D patients</arm_group_label>
    <description>Patients with renal tumour</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound Imaging</intervention_name>
    <description>3D volume calculation using on-line and off-line softwares</description>
    <arm_group_label>VolUS3D patients</arm_group_label>
    <other_name>3D Ultrasound transducer and fusion imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients (n=80) referred for renal tumour management (including imaging, biopsy or
        percutaneous ablation)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient (age 18)

          -  Absence of participant's opposition

          -  No contra-indication to contrast-enhanced CT AND MRI (a single contrast-enhanced
             imaging modality is sufficient)

          -  Affiliated to Social Security

        Exclusion Criteria:

        - Contra-indication to both contrast-enhanced CT AND MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel Correas, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Michel Correas, PU-PH</last_name>
    <phone>+33 1 44 49 41 40</phone>
    <email>jean-michel.correas@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>+33 1 71 19 63 46</phone>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Michel Correas, PU-PH</last_name>
      <phone>+33 1 44 49 41 40</phone>
      <email>jean-Michel.correas@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Morel</last_name>
      <phone>+33 1 71 1963 46</phone>
      <email>helene.morel@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>3D Ultrasound volume measurements</keyword>
  <keyword>Renal volume</keyword>
  <keyword>Tumour Volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

